FCL
Fineotex Chemical share price & financials
- Price
- ₹43.52
- Market cap
- ₹4.8k Cr
- Sector
- Chemicals
- Calls analysed
- 7
Fineotex Chemical Limited Q1 FY27
What went well
- Total income for Q1 FY27 stood at INR 386.72 crores, registering a 165% year-on-year growth.
- EBITDA for the quarter was INR 59.14 crores, a 134.7% Y-o-Y growth, with EBITDA margin at 15.70% (up from 13.93% last quarter).
- PAT increased by 92.67% Y-o-Y to INR 48.21 crores.
What to watch
- The Indian textile business showed a marginal decline (1-2% dip) in Q1 FY27, attributed to seasonality and competition.
What Fineotex Chemical Limited does
Fineotex Chemical manufactures tailor-made speciality performance chemicals used in textile wet-processing (pre-treatment, dyeing, printing, finishing), oilfield drilling and production (demulsifiers, corrosion inhibitors, biocides, surfactants), water treatment (scale-inhibiting polymers) and FMCG cleaning & hygiene products (floor cleaners, hand-washes, sanitizers, dishwashers). It earns by selling these customized chemical formulations to industrial customers through its own manufacturing plants and a dealer network across India and international markets. The group expanded into North American oilfield chemicals in December 2025 through a controlling stake in US-based CrudeChem Technologies Group, and runs its textile R&D through Malaysian subsidiary Biotex.
Segments
- Textile Specialty Chemicals
- Oil & Gas (Drilling & Oilfield Specialty Chemicals)
- Water Treatment
- FMCG, Cleaning & Hygiene
- Manufacturing plants
- 5 plants across India (Mahape, Ambernath), Malaysia (Selangor) and USA (Brookshire and Midland, Texas)
- Combined installed manufacturing capacity
- ~2,00,000 MTPA
- Countries with sales presence
- ~70 countries
- Product categories
- 470+
- SKUs across product categories
- 1,600+
- Dealer network
- 103+ dealers across Indian and international markets
Guidance record · Q1 FY27
what the last two calls moved 14 tracked 3 delivered 2 missed 9 open- CrudeChem EBITDA Margin delivered said Q3 FY26 Promised: Always double digits going forward (up from historical 7-8%) Q1 FY27: New guidance for CrudeChem EBITDA margin is 13-14%, confirming the 'double digits' target is being met.
- AquaStrike Premium Revenue went quiet said Q3 FY25 Promised: Substantial business from April onwards (Q1 FY26) Q1 FY27: No mention of AquaStrike in the earnings call or investor presentation.
- EBITDA Margin on track said Q4 FY25 Promised: Around 24% going forward Q1 FY27: Actual margin 15.7%, up from 14% last quarter. Progressing towards 18-20% target.
All 14 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 175.2%, net profit up 92.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 146 | 126 | 120 | 137 | 138 −5% | 184 +46% | 314 +162% | 377 +175% |
| EBITDA | 36 | 34 | 21 | 25 | 31 −14% | 35 +3% | 44 +110% | 59 +136% |
| Net profit | 32 | 28 | 20 | 25 | 26 −19% | 30 +7% | 44 +120% | 48 +92% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −76.2% 1Y
1Y: ₹242.35 on 10 Sept 2025 → ₹57.72. High ₹257.32 (29 Sept 2025), low ₹19.24 (30 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- −5.5%
- 24 Jul
- Q4 FY26
- +20.0%
- 18 May
- Q3 FY26
- +0.6%
- 16 Feb
- Q2 FY26
- −2.1%
- 10 Dec
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 14.3% a year over 3 years, FY23 to FY26. Operating margin narrowed to 17.5%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹517 Cr | ₹568 Cr | ₹534 Cr | ₹773 Cr |
| Operating profit | ₹113 Cr | ₹148 Cr | ₹126 Cr | ₹135 Cr |
| Operating margin | 21.9% | 26.1% | 23.6% | 17.5% |
| Interest | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Depreciation | ₹4 Cr | ₹5 Cr | ₹9 Cr | ₹13 Cr |
| Net profit | ₹89 Cr | ₹120 Cr | ₹109 Cr | ₹125 Cr |
| Net margin | 17.2% | 21.1% | 20.4% | 16.2% |
| Cash from operations | ₹107 Cr | ₹97 Cr | ₹69 Cr | ₹-24 Cr |
| Free cash flow | ₹88 Cr | ₹49 Cr | ₹1 Cr | ₹-49 Cr |
| ROCE | 36.0% | 39.0% | 24.0% | 18.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹23 Cr | ₹116 Cr |
| Reserves | ₹187 Cr | ₹240 Cr | ₹327 Cr | ₹425 Cr | ₹756 Cr | ₹766 Cr |
| Borrowings | ₹3 Cr | ₹2 Cr | ₹7 Cr | ₹5 Cr | ₹0 Cr | ₹8 Cr |
| Other liabilities | ₹54 Cr | ₹75 Cr | ₹67 Cr | ₹96 Cr | ₹98 Cr | ₹269 Cr |
| Total liabilities | ₹267 Cr | ₹339 Cr | ₹423 Cr | ₹548 Cr | ₹878 Cr | ₹1.2k Cr |
| Fixed assets | ₹59 Cr | ₹84 Cr | ₹99 Cr | ₹141 Cr | ₹198 Cr | ₹278 Cr |
| Capital work in progress | ₹5 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹8 Cr | ₹2 Cr |
| Investments | ₹32 Cr | ₹17 Cr | ₹89 Cr | ₹147 Cr | ₹348 Cr | ₹317 Cr |
| Other assets | ₹171 Cr | ₹238 Cr | ₹234 Cr | ₹260 Cr | ₹323 Cr | ₹562 Cr |
| Total assets | ₹267 Cr | ₹339 Cr | ₹423 Cr | ₹548 Cr | ₹878 Cr | ₹1.2k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Mutual funds in FCL
Filings to Aug 2026
0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).
- Held by funds
- ₹75 Cr
- 1 schemes
- Biggest holder
- Nippon India Small Cap Fund
- ₹75 Cr · 0.1% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Small Cap Fund Nippon India Mutual Fund | ₹75 Cr | held | Dec '20 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
- Funds are sitting on
- +523%
- vs est. average cost
- Held by funds
- ₹75 Cr
- 1 schemes · ≈ 1.4% of the company
Shares held by these funds −61%
Aug '23 1.48 cr shares Jul '26
What the price assumes
Growth trapTo justify its price of ₹58, this stock must grow earnings at 30% every year for 7 years. Our analysis caps realistic growth at ~12%. At that growth it is worth ₹23 — downside of 61%.
- Growth the price implies
- 30.4% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 12.0% a year
- net profit, FY23–FY26
- The gap
- 0.2 pp
- -61% downside if it only repeats history
All earnings calls (7)
Read the Q1 FY27 call →Learn to analyse Fineotex Chemical Limited
Guides on how to read this kind of business and the numbers that matter.